Works matching IS 11738804 AND DT 2021 AND VI 35 AND IP 4

Results: 8

Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis.

Published in:

BioDrugs, 2021, v. 35, n. 4, p. 401, doi. 10.1007/s40259-021-00490-x

By:

Yang, Nan;
Chen, Zeyu;
Zhang, Xilin;
Shi, Yuling

Publication type:

Article

Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC).

Published in:

BioDrugs, 2021, v. 35, n. 4, p. 417, doi. 10.1007/s40259-021-00489-4

By:

Syrigos, Konstantinos;
Abert, Istvan;
Andric, Zoran;
Bondarenko, Igor N;
Dvorkin, Mikhail;
Galic, Kristina;
Galiulin, Rinat;
Kuchava, Vladimer;
Sriuranpong, Virote;
Trukhin, Dmytro;
Zhavrid, Edvard;
Fu, Dongyue;
Kassalow, Laurent M;
Jones, Stephanie;
Bashir, Zahid

Publication type:

Article

Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar.

Published in:

BioDrugs, 2021, v. 35, n. 4, p. 459, doi. 10.1007/s40259-021-00487-6

By:

Courville, Jocelyn;
Nastoupil, Loretta;
Kaila, Nitin;
Kelton, John;
Zhang, Jeffrey;
Alcasid, Ann;
Nava-Parada, Pilar

Publication type:

Article

Comparability of Biologics: Global Principles, Evidentiary Consistency and Unrealized Reliance.

Published in:

BioDrugs, 2021, v. 35, n. 4, p. 379, doi. 10.1007/s40259-021-00488-5

By:

Webster, Christopher J.;
George, Kelly L.;
Woollett, Gillian R.

Publication type:

Article

Restoring Protein Expression in Neuromuscular Conditions: A Review Assessing the Current State of Exon Skipping/Inclusion and Gene Therapies for Duchenne Muscular Dystrophy and Spinal Muscular Atrophy.

Published in:

BioDrugs, 2021, v. 35, n. 4, p. 389, doi. 10.1007/s40259-021-00486-7

By:

Sheikh, Omar;
Yokota, Toshifumi

Publication type:

Article

Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis.

Published in:

2021

By:

Piaserico, Stefano;
Conti, Andrea;
Messina, Francesco;
Meneguzzo, Alberto;
Odorici, Giulia;
Bellinato, Francesco;
Gisondi, Paolo

Publication type:

Letter

Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study.

Published in:

BioDrugs, 2021, v. 35, n. 4, p. 445, doi. 10.1007/s40259-021-00484-9

By:

Qin, Shukui;
Li, Jin;
Bai, Yuxian;
Shu, Yongqian;
Li, Wei;
Yin, Xianli;
Cheng, Ying;
Sun, Guoping;
Deng, Yanhong;
Zhong, Haijun;
Li, Yunfeng;
Qian, Xiaoping;
Zhang, Liangming;
Zhang, Jingdong;
Chen, Kehe;
Kang, Wenying;
HLX04-mCRC03 Investigators;
Sun, Yuping;
Lin, Yuan;
Liu, Tianshu

Publication type:

Article

Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA).

Published in:

BioDrugs, 2021, v. 35, n. 4, p. 429, doi. 10.1007/s40259-021-00483-w

By:

Trukhin, Dmytro;
Poddubskaya, Elena;
Andric, Zoran;
Makharadze, Tamta;
Bellala, Ravi Shankar;
Charoentum, Chaiyut;
Yañez Ruiz, Eduardo P.;
Fulop, Andrea;
Hyder Ali, Irfhan Ali;
Syrigos, Kostas;
Katgi, Nuran;
Lopez Chuken, Yamil Alonso;
Rumyana, Ilieva;
Reyes-Igama, Jasmin;
Costamilan, Rita de Cassia;
Del Campo García, Ana;
Florez, Amalia;
Paravisini, Alexandra;
Millan, Susana;
for the STELLA Investigators

Publication type:

Article